Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma-Reference-Cited by-同舟云学术

Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma

Published:2011-06 Issue:4 Volume:43 Page:313-317
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Kao Steven Chuan-Hao,Griggs Kim,Lee Kenneth,Armstrong Nicola,Clarke Stephen,Vardy Janette,Zandwijk Nico van,Burn Juliet,McCaughan Brian C.,Henderson Douglas W.,Klebe Sonja

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference15 articles.

1. Killing the Future – Asbestos Use in Asia.;Kazan-Allen,2007

2. Malignant Mesothelioma.;Henderson,1992

3. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group;Husain;Arch Pathol Lab Med,2009

4. D2-40: a reliable marker in the diagnosis of pleural mesothelioma;Muller;Pathobiology,2006

5. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation;Hinterberger;Mod Pathol,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis of Mesothelioma;Surgical Pathology Clinics;2020-03

2. Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis;Oncotarget;2017-07-06

3. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma;The Annals of Thoracic Surgery;2017-03

4. Mesothelioma Pathology;Asbestos and Mesothelioma;2017

5. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach;Pathology - Research and Practice;2016-10